Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dupilumab: A Review of Present Indications and Off-Label Uses
Francisco J. Muñoz‐Bellido, Esther Moreno, Ignacio Dávila
Journal of Investigational Allergology and Clinical Immunology (2021) Vol. 32, Iss. 2, pp. 97-115
Open Access | Times Cited: 93

Showing 26-50 of 93 citing articles:

Dermatologic adverse events caused by biologic treatments – Pathogenesis and management
Laura Trefzer, Anna Caroline Pilz, Kilian Eyerich
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2024) Vol. 22, Iss. 8, pp. 1126-1136
Closed Access | Times Cited: 2
Cholinergic Urticaria, an Effective and Safe “Off Label” Use of Dupilumab: A Case Report with Literature Review
Maria Naddalena Sirufo, Alessandra Catalogna, Martina Raggiunti, et al.
Clinical Cosmetic and Investigational Dermatology (2022) Vol. Volume 15, pp. 253-260
Open Access | Times Cited: 10
Existing and Investigational Medications for Refractory Chronic Spontaneous Urticaria: Safety, Adverse Effects, and Monitoring
Emek Kocatürk, Sarbjit S. Saini, Christine J. Rubeiz, et al.
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 10, Iss. 12, pp. 3099-3116
Closed Access | Times Cited: 10
A clinical focus on oral tolerance in the development, prevention, and management of food allergy
Jessica Macdougall, Edwin Kim
Cellular Immunology (2023) Vol. 386, pp. 104693-104693
Closed Access | Times Cited: 6
Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study
S. Wang, Ying Shan, Sizhe Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Allergen immunotherapy: progress and future outlook
Lara Šošić, Marta Paolucci, Stephan Flory, et al.
Expert Review of Clinical Immunology (2023) Vol. 19, Iss. 7, pp. 745-769
Closed Access | Times Cited: 5
Analyses of Dupilumab-Related Ocular Adverse Drug Reactions Using the WHO’s VigiBase
E Hirai, Tomoko Haruki, Takashi Baba, et al.
Advances in Therapy (2023) Vol. 40, Iss. 9, pp. 3830-3856
Closed Access | Times Cited: 5
Biologics to treat anaphylaxis
Barbara Yang
Current Opinion in Allergy and Clinical Immunology (2023) Vol. 23, Iss. 5, pp. 370-375
Closed Access | Times Cited: 5
Changes in Peripheral Blood Eosinophil Counts and Risk of Eosinophilic Granulomatosis with Polyangiitis Onset after Initiation of Dupilumab Administration in Adult Patients with Asthma
Yoshitomo Kushima, Yasuo Shimizu, H Hoshi, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 17, pp. 5721-5721
Open Access | Times Cited: 4
Identification of a novel COL7A1 variant associated with dystrophic epidermolysis bullosa pruriginosa responding effectively to dupilumab
Caichou Zhao, Shuanglin Cao, Xinghua Gao, et al.
Molecular Genetics & Genomic Medicine (2023) Vol. 11, Iss. 11
Open Access | Times Cited: 4
IL‐4/IL‐13 pathway in nasal type 2 inflammation: The central role and targeted therapy
Zhiqiu Zhu, Chaoran Zhao, Ming Wang
Eye & ENT Research (2024) Vol. 1, Iss. 1, pp. 39-48
Open Access | Times Cited: 1
Unveiling the Intricacies of Autophagy in Asthma: Unraveling Novel Therapeutic Avenues
Junjun Peng, Na Lü, Shucheng Hua, et al.
Frontiers in Bioscience-Landmark (2024) Vol. 29, Iss. 1, pp. 22-22
Open Access | Times Cited: 1
The relationship between umbilical cord blood IL-22 level and infantile eczema at 42 days
Xujun Lu, Wenge Wang, Yang Wang, et al.
Frontiers in Pediatrics (2024) Vol. 12
Open Access | Times Cited: 1
Rapid response to dupilumab in an adult patient with eosinophilic esophagitis and allergic asthma
Benjamin Y. Klein, Regina Treudler
Allergologie select (2024) Vol. 8, Iss. 1, pp. 78-81
Open Access | Times Cited: 1
Efficacy, Safety, and Continuation of Biological Therapy in Older Patients with Asthma in a Real-World Setting: A Retrospective Observational Study
Ryota Okazaki, Tomoya Harada, Yoshihiro Funaki, et al.
Yonago acta medica (2024) Vol. 67, Iss. 2, pp. 114-123
Open Access | Times Cited: 1
Pearls for practice from the 2023 allergy immunology joint task force on practice parameters GRADE and institute of medicine based atopic dermatitis guidelines
Alexandra E. Conway, Navya Kartha, Chaitanya Maddukuri, et al.
Current Opinion in Pediatrics (2024) Vol. 36, Iss. 5, pp. 570-580
Closed Access | Times Cited: 1
Conventional and Novel Treatment Strategies for Porokeratoses: A Narrative Review
Yumeng La, Jie Zhu, Simon M. Mueller
JDDG Journal der Deutschen Dermatologischen Gesellschaft (2024) Vol. 22, Iss. 8, pp. 1073-1077
Closed Access | Times Cited: 1
From Pathogenesis to Treatment: Targeting Type-2 Inflammation in Eosinophilic Esophagitis
Alberto Barchi, Francesco Vito Mandarino, Mona‐Rita Yacoub, et al.
Biomolecules (2024) Vol. 14, Iss. 9, pp. 1080-1080
Open Access | Times Cited: 1
The causal relationship between negative emotions and inflammatory dermatoses: a bidirectional Mendelian randomization study
Keyi Zhang, Mingwei Zeng, Lei Li, et al.
Postgraduate Medical Journal (2024)
Closed Access | Times Cited: 1
Dupilumab to induce tolerance to SLIT-Melocotón®
M.S. Zamarro Parra, Y. Petryk Petryk, S. San Román Sirvent, et al.
European Annals of Allergy and Clinical Immunology (2023) Vol. 56, Iss. 03, pp. 137-137
Open Access | Times Cited: 3
Hyperthyroidism in a 15-year-old adolescent treated with Dupilumab for severe allergic asthma and atopic dermatitis
Maria Angela Tosca, Roberta Olcese, Donata Girosi, et al.
Allergologia et Immunopathologia (2023) Vol. 51, Iss. 3, pp. 181-185
Open Access | Times Cited: 3
Efficacy and Safety of Dupilumab in Older Patients (Aged 80 Years and Above) with Atopic Dermatitis: A Prospective Study
Xiyuan Zhou, Ge Yang, Xuejun Chen, et al.
Drugs & Aging (2023) Vol. 40, Iss. 10, pp. 933-940
Open Access | Times Cited: 3
Global influence of dupilumab on Quality of Life in a severe asthma patient with T2 multimorbidities: a case report on atopic dermatitis, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis
Mónica Colque-Bayona, Natalia Hernández‐Cano, Margarita Tomás‐Pérez, et al.
Journal of Asthma (2023) Vol. 61, Iss. 7, pp. 762-765
Closed Access | Times Cited: 3
Biologic therapies for hypereosinophilic disorders: From tyrosine kinase inhibitors to monoclonal antibodies. Towards an increasingly customized management?
Alessandra Iurlo, Daniele Cattaneo
Blood Reviews (2022) Vol. 58, pp. 101014-101014
Closed Access | Times Cited: 4
Il dupilumab nell’esofagite eosinofila: una nuova frontiera?
Martina Mainetti, Angela Troisi, Giuliana Turlà, et al.
Medico e Bambino (2022) Vol. 41, Iss. 1, pp. 583-587
Closed Access | Times Cited: 4

Scroll to top